BACKGROUND: CD44 and aldehyde dehydrogenase 1 (ALDH1) are considered putative markers of highly tumorigenic cells (i.e., cancer stem-like cells) in head and neck squamous cell carcinomas. This small subset of cells is believed to be the primary responsible for tumor initiation and progression. The objectives of this study were (i) to evaluate the patterns of CD44 and ALDH1 expression in the tumor center and in the invasive front, as well as in adjacent non-tumor epithelium, and (ii) to correlate these findings with clinical parameters. MATERIALS AND METHODS: The sample comprised 44 patients with primary head and neck squamous cell carcinomas. Hematoxylin and eosin (HE) staining was used for histopathological tumor grading and for morphological analysis of adjacent non-tumor epithelium. Semiquantitative analysis was performed in histological sections immunostained for CD44 and ALDH1. RESULTS: ALDH1 immunostaining in the invasive front showed positive association with tumor size, regional metastasis, tumor histopathological grading, and disease progression. Moreover, expression of this marker in both tumor invasive front and adjacent non-tumor epithelium was related with more aggressive tumors. CD44 immunostaining was heterogeneous in all areas evaluated and did not show association with clinical data. CONCLUSION: Collectively, these data suggest that ALDH1 immunostaining in the invasive front and in adjacent non-tumor epithelium may help identify tumors with a more aggressive behavior, potentially contributing to improving treatment customization and the monitoring of patients with head and neck cancer.
BACKGROUND:CD44 and aldehyde dehydrogenase 1 (ALDH1) are considered putative markers of highly tumorigenic cells (i.e., cancer stem-like cells) in head and neck squamous cell carcinomas. This small subset of cells is believed to be the primary responsible for tumor initiation and progression. The objectives of this study were (i) to evaluate the patterns of CD44 and ALDH1 expression in the tumor center and in the invasive front, as well as in adjacent non-tumor epithelium, and (ii) to correlate these findings with clinical parameters. MATERIALS AND METHODS: The sample comprised 44 patients with primary head and neck squamous cell carcinomas. Hematoxylin and eosin (HE) staining was used for histopathological tumor grading and for morphological analysis of adjacent non-tumor epithelium. Semiquantitative analysis was performed in histological sections immunostained for CD44 and ALDH1. RESULTS:ALDH1 immunostaining in the invasive front showed positive association with tumor size, regional metastasis, tumor histopathological grading, and disease progression. Moreover, expression of this marker in both tumor invasive front and adjacent non-tumor epithelium was related with more aggressive tumors. CD44 immunostaining was heterogeneous in all areas evaluated and did not show association with clinical data. CONCLUSION: Collectively, these data suggest that ALDH1 immunostaining in the invasive front and in adjacent non-tumor epithelium may help identify tumors with a more aggressive behavior, potentially contributing to improving treatment customization and the monitoring of patients with head and neck cancer.
Authors: Stefan Hartmann; Muna Brisam; Stephan Rauthe; Oliver Driemel; Roman C Brands; Andreas Rosenwald; Alexander C Kübler; Urs D A Müller-Richter Journal: Oncol Lett Date: 2016-08-03 Impact factor: 2.967
Authors: Sabrina Daniela da Silva; Grégoire B Morand; Faisal A Alobaid; Michael P Hier; Alex M Mlynarek; Moulay A Alaoui-Jamali; Luiz Paulo Kowalski Journal: Clin Exp Metastasis Date: 2014-11-30 Impact factor: 5.150
Authors: Kelsey A Finkel; Kristy A Warner; Samuel Kerk; Carol R Bradford; Scott A McLean; Mark E Prince; Haihong Zhong; Elaine M Hurt; Robert E Hollingsworth; Max S Wicha; David A Tice; Jacques E Nör Journal: Neoplasia Date: 2016-04-15 Impact factor: 5.715
Authors: Mark Jakob; Kariem Sharaf; Markus Schirmer; Martin Leu; Stefan Küffer; Mattis Bertlich; Friedrich Ihler; Frank Haubner; Martin Canis; Julia Kitz Journal: Strahlenther Onkol Date: 2020-06-25 Impact factor: 3.621
Authors: Kariem Sharaf; Axel Lechner; Stefan P Haider; Robert Wiebringhaus; Christoph Walz; Gisela Kranz; Martin Canis; Frank Haubner; Olivier Gires; Philipp Baumeister Journal: Curr Oncol Date: 2021-07-19 Impact factor: 3.677